Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

PET imaging in oncology.

R Bar-Shalom1, A Y Valdivia, M D Blaufox

  • 1Department of Nuclear Medicine, Albert Einstein College of Medicine and Montefiore Medical Center, Bronx, NY, USA.

Seminars in Nuclear Medicine
|August 6, 2000
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Patterns of FDG uptake in post-thoracotomy surgical scars in patients with lung cancer.

The British journal of radiology·2008
Same author

Multimodality imaging of direct ureteric involvement in non-Hodgkin's lymphoma using PET/CT, CT urography and antegrade CT pyelography.

The British journal of radiology·2007
Same author

Positron emission tomography/computed tomography with 18fluoro-deoxyglucose in the detection of local recurrence and distant metastases of pediatric sarcoma.

Pediatric blood & cancer·2007
Same author

18F-FDG PET of clear cell (sugar) tumour of the lung.

Nuklearmedizin. Nuclear medicine·2005
Same author

The neural correlates of understanding the other's distress: a positron emission tomography investigation of accurate empathy.

NeuroImage·2005
Same author

Disappearance of diffuse calcinosis following autologous stem cell transplantation in a child with autoimmune disease.

Bone marrow transplantation·2004
Same journal

Letter from the Editors.

Seminars in nuclear medicine·2026
Same journal

Expanding Horizons: The Role of Kaleidoscope and Relevant Images in Seminars in Nuclear Medicine.

Seminars in nuclear medicine·2026
Same journal

The diagnostic performance and clinical value of [18F]FDG PET/CT in pleural mesothelioma - A systematic review and meta-analysis.

Seminars in nuclear medicine·2026
Same journal

Feasibility of treating neuroendocrine prostate cancer with anti-SSTR radioligands: A systematic review of imaging and treatment studies.

Seminars in nuclear medicine·2026
Same journal

<sup>18</sup>F-FDG -PET/CT in cardiac sarcoidosis: Diagnosis, therapy monitoring, and future directions.

Seminars in nuclear medicine·2026
Same journal

Maximizing diagnostic yield: A systematic review and deep dive into PSMA PET scan protocol variations for prostate cancer.

Seminars in nuclear medicine·2026
See all related articles

Positron emission tomography (PET) is a powerful imaging tool in oncology, particularly using Fluorine-18 fluorodeoxyglucose (FDG). PET effectively stages cancer, differentiates tumors, and shows high accuracy in various cancers.

Area of Science:

  • Oncology
  • Medical Imaging
  • Nuclear Medicine

Background:

  • Positron emission tomography (PET) has transitioned from a research tool to a clinically significant methodology.
  • PET imaging is approved in the US for lung, lymphoma, colon, and melanoma.
  • Its application in oncology has seen rapid development and widespread adoption.

Purpose of the Study:

  • To review the evolving role and clinical potential of PET in oncology.
  • To highlight the efficacy of Fluorine-18 fluorodeoxyglucose (FDG) PET in cancer diagnosis and management.
  • To discuss the future prospects of PET technology in oncologic imaging.

Main Methods:

  • Review of current literature and clinical applications of PET in oncology.
  • Focus on the use of Fluorine-18 fluorodeoxyglucose (FDG) as a primary radiopharmaceutical.

Related Experiment Videos

  • Analysis of diagnostic accuracy (sensitivity and specificity) in various tumor types.

    • Main Results:

    • PET imaging, particularly FDG-PET, demonstrates high sensitivity and specificity (often >90%) in detecting and staging a wide range of malignant tumors.
    • FDG uptake is observed in head and neck, ovarian, breast, musculoskeletal, and neuroendocrine cancers.
    • PET is crucial for evaluating recurrent disease and differentiating benign from malignant primary tumors, notably solitary lung nodules.

    Conclusions:

    • PET, especially FDG-PET, has become an indispensable tool in oncologic imaging for staging, recurrence detection, and differential diagnosis.
    • Ongoing research into novel radiopharmaceuticals promises further advancements in PET's specificity and efficacy.
    • PET technology is poised for significant growth in oncologic applications over the next decade.